MoneyWorks4Me

Biocon informs about press release

21 Sep 2026 Evaluate
Biocon has informed that it enclosed the press release titled ‘Biocon’s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach’. The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
Sun Pharma. Inds. 1851.00
Dr. Reddys Labs. 1214.95
Cipla 1367.00
Lupin 2116.80
Zydus Lifesciences 1172.00
View more..